Investigation of Kinetics of Methotrexate for Therapeutic Treatment of Intraocular Lymphoma

REFERENCES

• National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: Summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer. 1982;49:2112–2135.
   PubMed Web of Science ®Google Scholar
• Barr CC, Green WR, Payne JW, et al. Intraocular reticulum-cell sarcoma: Clinico-pathologic study of four cases and review of the literature. Surv Ophthalmol. 1975;19:224–239.
   PubMedGoogle Scholar
• Augsburger JJ, Greatrex KV. Intraocular lymphoma: Clinical presentations, differential diagnosis and treatment. Trans Pa Acad Ophthalmol Otolaryngol. 1989;41:796–808.
   PubMedGoogle Scholar
• Walton RC, Onciu MM, Irshad FA, et al. Conjunctival posttransplantation lymphoproliferative disorder. Am J Ophthalmol. 2007;143:1050–1051.
   Google Scholar
• Chan CC, Wallace DJ. Intraocular lymphoma: Update on diagnosis and management. Cancer Control. 2004;11:285–295.
   PubMedGoogle Scholar
• Verity DH, Graham EM, Carr R, et al. Hypopyon uveitis and iris nodules in non-Hodgkin’s lymphoma: Ocular relapse during systemic remission. Clin Oncol (R Coll Radiol). 2000;12:292–294.
   PubMed Web of Science ®Google Scholar
• Batchelor TT, Kolak G, Ciordia R, et al. High-dose methotrexate for intraocular lymphoma. Clin Cancer Res. 2003;9:711–715.
   PubMed Web of Science ®Google Scholar
• Velez G, Yuan P, Sung C, et al. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary intraocular lymphoma. Arch Ophthalmol. 2001;119:1518–1524.
   PubMedGoogle Scholar
• Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience. Br J Ophthalmol. 2008;92:383–388.
   PubMed Web of Science ®Google Scholar
• Geroski DH, Edelhauser HF. Drug delivery for posterior segment eye disease. Invest Ophthalmol Vis Sci. 2000;41:961–964.
   PubMed Web of Science ®Google Scholar
• Yasukawa T, Ogura Y, Sakurai E, et al. Intraocular sustained drug delivery using implantable polymeric devices. Adv Drug Deliv Rev. 2005;57:2033–2046.
   PubMed Web of Science ®Google Scholar
• Berger AS, Cheng CK, Pearson PA, et al. Intravitreal sustained release corticosteroid-5-fluoruracil conjugate in the treatment of experimental proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1996;37:2318–2325.
   PubMed Web of Science ®Google Scholar
• Sakurai E, Matsuda Y, Ozeki H, et al. Scleral plug of biodegradable polymers containing ganciclovir for experimental cytomegalovirus retinitis. Invest Ophthalmol Vis Sci. 2001;42:2043–2048.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Ben-Nun J, Guo H, et al. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000;107:2024–2033.
   PubMed Web of Science ®Google Scholar
• Jaffe GJ, Pearson PA, Ashton P. Dexamethasone sustained drug delivery implant for the treatment of severe uveitis. Retina. 2000;20:402–403.
   PubMed Web of Science ®Google Scholar
• Shin JP, Park YC, Oh JH, et al. Biodegradable intrascleral implant of triamcinolone acetonide in experimental uveitis. J Ocul Pharmacol Ther. 2009;25:201–208.
   PubMed Web of Science ®Google Scholar
• Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: Therapeutic applications. Adv Drug Deliv Rev. 2006;58:1182–1202.
   PubMed Web of Science ®Google Scholar
• Hashizoe M, Ogura Y, Takanashi T, et al. Biodegradable polymeric device for sustained intravitreal release of ganciclovir in rabbits. Curr Eye Res. 1997;16:633–639.
   PubMed Web of Science ®Google Scholar
• Kunou N, Ogura Y, Yasukawa T, et al. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Release. 2000;68:263–271.
   PubMed Web of Science ®Google Scholar
• Park J. Treatment of intraocular lymphoma using biodegradable microneedle implant. Ph.D. Dissertation, University of Cincinnati, Cincinnati, Ohio, 2006.
   Google Scholar
• de Smet MD, Vancs VS, Kohler D, et al. Intravitreal chemotherapy for the treatment of recurrent intraocular lymphoma. Br J Ophthalmol. 1999;83:448–451.
   PubMed Web of Science ®Google Scholar
• Araie M, Maurice DM. The loss of fluorescein, fluorescein glucuronide and fluorescein isothiocyanate dextran from the vitreous by the anterior and retinal pathways. Exp Eye Res. 1991;52:27–39.
   PubMed Web of Science ®Google Scholar
• Friedrich S, Cheng YL, Saville B. Drug distribution in the vitreous humor of the human eye: The effects of intravitreal injection position and volume. Curr Eye Res. 1997;16:663–669.
   PubMed Web of Science ®Google Scholar
• Friedrich S, Cheng YL, Saville B. Finite element modeling of drug distribution in the vitreous humor of the rabbit eye. Ann Biomed Eng. 1997;25:303–314.
   PubMed Web of Science ®Google Scholar
• Krishnamoorthy MK, Park J, Augsburger JJ, et al. Effect of retinal permeability, diffusivity, and aqueous humor hydrodynamics on pharmacokinetics of drugs in the eye. J Ocul Pharmacol Ther. 2008;24:255–267.
   Google Scholar
• Park J, Bungay PM, Lutz RJ, et al. Evaluation of coupled convective-diffusive transport of drugs administered by intravitreal injection and controlled release implant. J Control Release. 2005;105:279–295.
   PubMed Web of Science ®Google Scholar
• Stay MS, Xu J, Randolph TW, et al. Computer simulation of convective and diffusive transport of controlled-release drugs in the vitreous humor. Pharm Res. 2003;20:96–102.
   PubMed Web of Science ®Google Scholar
• Goldberg S, Frenkel S, Blumenthal EZ, et al. Intraocular lymphoma. Ophthalmology. 2007;114:1236–1237.
   Google Scholar
• de Smet MD. Management of non Hodgkin’s intraocular lymphoma with intravitreal methotrexate. Bull Soc Belge Ophtalmol. 2001;279:91–95.
   Google Scholar
• Tojo K, Nakagawa K, Morita Y, et al. A pharmacokinetic model of intravitreal delivery of ganciclovir. Eur J Pharm Biopharm. 1999;47:99–104.
   Google Scholar
• Karma A, von Willebrand EO, Tommila PV, et al. Primary intraocular lymphoma: improving the diagnostic procedure. Ophthalmology. 2007;114:1372–1377.
   PubMed Web of Science ®Google Scholar
• Smith JR, Rosenbaum JT, Wilson DJ, et al. Role of intravitreal methotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmology. 2002;109:1709–1716.
   PubMed Web of Science ®Google Scholar
• Wang JK, Yang CM, Lin CP, et al. An Asian patient with intraocular lymphoma treated by intravitreal methotrexate. Jpn J Ophthalmol. 2006;50:474–478.
   Google Scholar
• Ashton P, Brown JD, Pearson PA, et al. Intravitreal ganciclovir pharmacokinetics in rabbits and man. J Ocul Pharmaco. 1992;8:343–347.
   PubMedGoogle Scholar
• Pitkanen L, Ranta VP, Moilanen H, et al. Permeability of retinal pigment epithelium: Effects of permeant molecular weight and lipophilicity. Invest Ophthalmol Vis Sci. 2005;46:641–646.
   PubMed Web of Science ®Google Scholar
• Prausnitz MR, Noonan JS. Permeability of cornea, sclera, and conjunctiva: A literature analysis for drug delivery to the eye. J Pharm Sci. 1998;87:1479–1488.
   PubMed Web of Science ®Google Scholar
• Moldow B, Larsen M, Sander B, et al. Passive permeability and outward active transport of fluorescein across the blood-retinal barrier in early ARM. Br J Ophthalmol. 2001;85:592–597.
   Google Scholar
• Yoshida A, Ishiko S, Kojima M. Outward permeability of the blood-retinal barrier. Graefes Arch Clin Exp Ophthalmol. 1992;230:78–83.
   PubMed Web of Science ®Google Scholar
• Yoshida A, Ishiko S, Kojima M. Inward and outward permeability of the blood-retinal barrier in experimental myopia. Graefes Arch Clin Exp Ophthalmol. 1996;234:S239–S242.
   Google Scholar
• Whitcup SM, GL Ross, ML, et al. Sustained release methotrexate implants for the treatment of intraocular lymphoma. Invest Ophthalmol Vis Sci. 2000;41:S770.
   Google Scholar